Could your diet influence chemo success? new study investigates
NCT ID NCT06483997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 100 women with breast or gynecologic cancers to see if their diet before chemotherapy is linked to levels of a protein called hepcidin, and whether hepcidin levels affect how much chemo they can receive. The goal is to understand if eating certain foods might help patients tolerate chemotherapy better. No new treatments are being tested.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand how diet and hepcidin levels influence chemotherapy effectiveness and side effects, potentially leading to dietary recommendations for cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks for associations, so it cannot prove cause and effect. Results may not lead to any changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
100 women receiving chemotherapy for breast or gynecological cancer at GW Cancer Center from July, 2024 - July, 2026
- Ages
-
21 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Have been diagnosed with invasive breast cancer, OR * Have been diagnosed with epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, OR * Have been diagnosed with endometrial cancer * Are chemotherapy-naïve * Are scheduled to receive neoadjuvant chemotherapy (or adjuvant chemotherapy following lumpectomy for breast cancer patients) or neoadjuvant/induction chemotherapy for gynecological cancer at GW Cancer Center Exclusion Criteria: * Prior primary hematological condition that would cause abnormal blood counts (e.g. leukemia) * Pregnant at the time of potential enrollment * Receipt of erythropoietin-stimulating agents or blood transfusion in the 6 weeks prior to initial testing * Women who are cognitively unable to provide a diet history for the month prior to assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer female are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
George Washington University Cancer Center
Washington D.C., District of Columbia, 20052, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Triple oral drug combo targets two stubborn gynecologic cancers
- Can an oral drug replace injections for advanced breast cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues